English

HONGKONG XINCHENG GONGCHUANG TECHNOLOGY CO., LTD.

HONGKONG XINCHENG GONGCHUANG TECHNOLOGY CO., LTD.

Home > Products > Pharmaceutical Raw Materials > Pharmaceutical Raw Materials Anti Estrogen Powder Raloxifene Hydrochloride
 

Pharmaceutical Raw Materials Anti Estrogen Powder Raloxifene Hydrochloride

  • Pharmaceutical Raw Materials Anti Estrogen Powder Raloxifene Hydrochloride
Place of Origin:
China
Brand Name:
GONGCHUANG
Certification:
ISO9001,USP,KOSHER,etc
Model Number:

SARM

Min.Order Quantity:
10gram
Price:
negotiable
Packaging Details:
25k/Drum
Delivery Time:
arrange package within 2working days after payment
Payment Terms:
T/T, Western Union, MoneyGram,bitcoin
Supply Ability:
500kg+ each week
Contact Now
 

Product Description

Pharmaceutical Raw Materials Anti Estrogen Powder Raloxifene Hydrochloride Raloxifene HCl

Anti-Cancer API 99% Raloxifene hcl CAS 84449-90-1

Raloxifene Hydrochloride Use in Cancer
Raloxifene hydrochloride is approved to prevent: Breast cancer.
Raloxifene hydrochloride is used to decrease the chance of invasive breast cancer in postmenopausal women who have a high risk for developing the disease or who have osteoporosis.
Raloxifene hydrochloride is also approved to prevent and treat:Osteoporosis in postmenopausal women.
Raloxifene hydrochloride is also being studied in the treatment of other types of cancer.

Product name Raloxifene hydrochloride
Other name Raloxifene HCL;KEOXIFENE;AKOS 92138
Possible similar drug Evista; Evista
CAS register number 82640-04-8
Steroid Class Anti Estrogen Steroids
Appearance Light yellow powder
Molecular formula C28H28ClNO4S
Molecular weight 510.04
Melting point 250-253°C
Assay 99%
Brand vanz
Manufacturer vanz
Treatment for the treatment/prevention of osteoporosis and reduction of breast cancer riskinpostmenopausalwomen.
Storage Shading, confined preservation



Certificate of Analysis

ITEMS SPECIFICATION RESULT
Appearance White &off-white powder Conforms
Grade Anti Estrogen Steroids Conforms
Solubility Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water Conforms
Identifications Infrared Absorption Conforms
Loss on drying ≤0.5% 0.4%
Residue on ignition ≤0.1% 0.06%
Heavy metals ≤10ppm Conforms
Raloxifene Impurity1 ≤0.20 % 0.10%
Any unspecified individual impurity 2 ≤0.10% Max. 0.08%
Total impurities ≤0.50% 0.40%
Raloxifene HCl ≥98.0% 99.0%


We are also provide :

pregabalin 148553-50-8
Glutathione 70-18-8
Ibudilast 50847-11-5
Orlistat 96829-58-2
Rapamycin 53123-88-9
Sofosbuvir 1190307-88-0
Galantamine Hydrobromide 1953-4-4
DextroMethorphan HCL 125-71-3
Memantine HCl 41100-52-1
5a Hydrolaxogenin 1177-71-5
Raloxifene hydrochloride 82640-04-8
TUDCA 14605-22-2
ITPP 802590-64-3
Dutasteride 164656-23-9
Finasteride 98319-26-7
RU 58841 154992-24-2
Triiodothyronine sodium 55-06-1
L-Thyroxine 51-48-9
Minoxidil 38304-91-5
Enzalutamide 915087-33-1
Telmisartan 144701-48-4
Yohimbine hydrochloride 65-19-0
Oseltamivir phosphate 204255-11-8
Everolimus 159351-69-6

 

 

Vinpocetine 42971-09-5
Vincamine 1617-90-9
phenibut 1078-21-3
cdp-colina 987-78-0
Citicoline sodium 33818-15-4
IDRA-21 22503-72-6
adrafinil 63547-13-7
Melanotan2  
Tianeptine Sulfate 1224690-84-9
Tianeptine sodium 30123-17-2
Tianeptine acid 66981-73-5
magnesium L-Theorate 778571-57-6
Sulbutiamine 3286-46-2
NSI-189 Freebase and phosphate 1270138-40-3
phenylpiracetam 77472-70-9
Noopept 157115-85-0
Alpha-GPC 28319-77-9
Coluracetam 135463-81-9
Oxiracetam 62613-82-5
Piracetam 7491-74-9
NSI-189 1270138-40-3
Sunifiram 314728-85-3
Fasoracetam 110958-19-5
Citicoline sodium 33818-15-4
Pramiracetam  

Description:

Raloxifene hydrochlorideis an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4SHCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale yellow solid that is very slightly soluble in water.

EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 g of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrouslactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol,and titanium dioxide.



Application:

May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.

Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).

Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.

 

 

Raloxifene Hcl Application:

May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer inpostmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).
Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established. Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. 1 Not indicated for reduction in the risk of noninvasive breast cancer.

Uses for Raloxifene Hydrochloride

Osteoporosis

Prevention of osteoporosis in postmenopausal women.

Treatment of osteoporosis in postmenopausal women.

Use supplemental calcium and/or vitamin D concomitantly if daily dietary intake is considered in adequate.

Corticosteroid-induced Osteoporosis

May prevent or treat corticosteroid-induced bone loss†. American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.

Breast Cancer

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.

Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.

Not indicated for the treatment of breast cancer or to reduce the risk of recurrence of breast cancer. Not indicated for reduction in the risk of noninvasive breast cancer.

 
 

Pharmaceutical Raw Materials Anti Estrogen Powder Raloxifene Hydrochloride Images

 

Send Inquiry

*Email

Please Enter your Email Address

Subject

Inquiry About

Quick question
Please select FAQ

I'm very interested in your products; could you send me some detail reference information?

Please send me detail product specification, thank you!

May I be an agency of your products,and what's yourterms?

We intend to purchase this product, would you please send me the quotation and minimum order quantity?

*Message
I want to buy

For the best results, we recommend including the following details: -Self introduction -Required specifications -Inquire about price/MOQ